Clinical trials: Anal Carcinoma
Oropharyngeal Cancer, Neck Cancer
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Background: Often, metastatic human papillomavirus (HPV) associated cancers cannot be cured. They also do not respond well to treatment. Some forms of colon cancer also have poor responses to treatment.
- Conditions
- Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV
- Trial name
- NCT04708470
- Testing
- Bintrafusp Alfa, PDS01ADC, Entinostat
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started…
- Conditions
- Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
- Trial name
- NCT02314169
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 56 sites in United States, Canada
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Vaginal Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer
- Trial name
- NCT02280811
- Testing
- Fludarabine, Cyclophosphamide, E6 TCR
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus Infection
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
This study is to evaluate the safety and tolerability profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy women ages 18-45
- Trial name
- NCT05680454
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Malignant Neoplasm, Malignant Neoplasm of Rectum
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
The investigators hypothesize that an increase in dietary fiber intake during radiation therapy may provide better long-term intestinal health for the cancer survivor.
- Conditions
- Malignant Neoplasm, Malignant Neoplasm of Rectum, Malignant Neoplasm of Anus, Malignant Neoplasm of Urinary Bladder
- Trial name
- FIDURA (NCT04534075)
- Where
- Sweden
- Volunteers
- 354 people
- Sponsor
- Sahlgrenska University Hospital
Squamous Cell Carcinoma of the Anal Canal
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
- Trial name
- NCT04472429
- Testing
- carboplatin, paclitaxel, retifanlimab
- Where
- 84 sites in United States, Australia and 11 more
- Volunteers
- 308 people
- Sponsor
- Incyte Corporation
Anal Carcinoma
Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy
Randomized study to investigate the efficacy of deep regional hyperthermia in patients with anal carcinoma treated by standard radiochemotherapy with MMC and 5-FU.
- Trial name
- HYCAN (NCT02369939)
- Testing
- Irradiation, Mitomycin C, 5-Fluorouracil
- Where
- Germany
- Volunteers
- 118 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune…
- Trial name
- NCT05662020
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
- Where
- China
- Volunteers
- 2,750 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Carcinoma of the Anal Canal
Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma
This research study is a Pilot Study. Pilot studies are conducted to see if it is practical to do this type of research ona larger scale in the future.
- Trial name
- NCT01858025
- Testing
- Pencil Beam scanning Radiation, 5-fluorouracil, Mitomycin-C
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Advanced Cancer, Squamous Cell Carcinoma
A Phase 1 Study in Participants With Advanced Cancer
The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1[chk 1]) in participants with advanced or metastatic cancer (Part A), or squamous cell…
- Conditions
- Advanced Cancer, Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Lung Squamous Cell Carcinoma Stage IV
- Trial name
- NCT01115790
- Testing
- Prexasertib
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Anal, Colon, and Rectal Cancers, Head and Neck Cancer
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
Cetuximab, erlotinib, and panitumumab are all recently FDA approved epidermal growth factor receptor (EGFR) inhibitors that treat a wide variety of tumor types, such as colon, lung, and head and neck.
- Conditions
- Anal, Colon, and Rectal Cancers, Head and Neck Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT01137162
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Head and Neck Squamous Cell Carcinoma, Lung Cancer
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
- Trial name
- ABIMMUNE (NCT03212469)
- Testing
- Durvalumab, Tremelimumab, SBRT
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Rectal Cancer, Colon Cancer
Molecular Genetic and Pathological Studies of Anal Tumors
Study the Genetics of Anal Cancer
- Conditions
- Rectal Cancer, Colon Cancer, Colonic Neoplasms, Anal Cancer
- Trial name
- NCT00267787
- Testing
- genetic analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Anal Cancer, Squamous Cell Carcinoma, Radiation Exposure
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
Over 80% of anal cancers are squamous cell carcinoma (SCC). Current standard treatment for locally advanced squamous cell carcinoma of the anal canal is a combination of radiation therapy (RT) and concurrent chemotherapy.
- Trial name
- NCT03386500
- Testing
- BMX-001
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Nebraska
Squamous Cell Carcinoma of the Anus
The Self-Sampling Pilot Study
The investigators will test the cytological performance of a nylon-flocked swab at two insertion depths in the anus, 3 cm and 5 cm, to determine which insertion depth is better at collecting cells from the squamocolumnar junction…
- Trial name
- SOLOPilot (NCT07085845)
- Testing
- Inserting a swab 5 cm into the anus during self-sampling, Self-sampling with a swab by inserting the swab 3 cm into the anus.
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer.
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
- Trial name
- NCT03233711
- Testing
- Biopsy Procedure, Biospecimen Collection, Colonoscopy
- Where
- 896 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- National Cancer Institute (NCI)
Anal Cancer, Precancerous Condition
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
RATIONALE: High-grade squamous intraepithelial lesions of the skin near the anus are caused by the human papillomavirus (HPV). Antiviral drugs,, such as cidofovir, act against viruses and may stop these lesions from becoming…
- Trial name
- NCT00550589
- Testing
- cidofovir, DNA methylation analysis, gene expression analysis
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- AIDS Malignancy Consortium
Localized Anal Carcinoma, Localized Anal Margin Carcinoma
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized).
- Conditions
- Localized Anal Carcinoma, Localized Anal Margin Carcinoma, Stage 0 Anal Cancer AJCC v8, Stage I Anal Cancer AJCC v8
- Trial name
- NCT07112690
- Testing
- Electronic Health Record Review, Fluoroscopy, Ganglion Impar Neurolysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Squamous Cell Carcinoma of the Anus Stage III
Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.
Squamous cell carcinoma of the anus (SCCA) is a rare cancer, however its incidence is increasing worldwide. SCCA is mostly induced by human papillomavirus (HPV) infections (high-risk types such as HPV-16 and -18) and HPV-related…
- Trial name
- INTERACT-ION (NCT04719988)
- Testing
- Blood sample collection, Biopsy
- Where
- 10 sites in France
- Volunteers
- 55 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology